Stereotaxis
St. Jude Medical seesaws on FDA warning letter
A warning letter from the FDA to St. Jude Medical (NYSE:STJ) sent the St. Paul, Minn.-based medical device company’s stock on a seesaw ride yesterday and today.
STJ shares closed up 1.5% yesterday at $38.85 each after St. Jude revealed the warning letter, but closed down 1.2% today at $38.39 apiece.
Amedica promotes Bryan McEntire to chief tech exec | Personnel Moves
Accuray slides on lowered sales outlook | Earnings Roundup
Accuray (NSDQ:ARAY) shares are down nearly 10% today as investors react to wider 3rd-quarter losses and a lower sales forecast for the rest of fiscal 2012.
The Sunnyvale, Calif.-based radiosurgery device maker reported losses of $14.9 million, or 21¢ per share, on sales of $101.8 million during the 3 months ended March 31.
St. Jude Medical’s largest backer boosts stake by 30% | Wall Street Beat
St. Jude Medical‘s (NYSE:STJ) largest investor boosted its stake by more than 30%, to some 27.2 million shares, or about 10% of the medical device maker.
Bovie swings to 2011 black | Earnings Roundup
Abbott brass takes pay cuts | Personnel Moves
Elekta’s Q3 sales spike, earnings soar | Earnings Roundup
“Exit hangover” casts a pall on private equity | Wall Street Beat
Private equity players are in for some stiff competition this year, as large-cap PE shops invade the middle-market space, according to a report from PE stalwart Bain & Co.
The company’s Global PE Report details a huge “exit overhang” – more aptly deemed an “exit hangover” by PE Hub’s Jonathan Marino – as PE-backed companies seek exits.
And the mega-deals of the past 10 years or so are a thing of the past, according the report, as detailed by Marino.
Edwards lands CE Mark for Intuity valve | Regulatory Roundup
Edwards Lifesciences Corp. (NYSE:EW) landed CE Mark approval in the European Union for its Intuity valve system.
The Intuity valve, made of bovine pericardial tissue, is a minimally invasive option for patients in need of aortic valve replacement.
Stereotaxis shares risk delisting as share prices linger below $1
Stereotaxis (NSDQ:STXS) received notice from the NASDAQ stock exchange that it could be delisted if its share prices stay below the $1 mark.
The robotic cardiac surgical systems maker has until July 18 to boost its share value, which has been trading under the $1 mark since closing at 95 cents Dec. 7, 2011.
Shares have hovered around 80 cents for most of January and closed at 80 cents today.